Erik Swenson to Carbonic Anhydrase Inhibitors
This is a "connection" page, showing publications Erik Swenson has written about Carbonic Anhydrase Inhibitors.
Connection Strength
1.783
-
Acetazolamide Use in Severe Chronic Obstructive Pulmonary Disease. Pros and Cons. Ann Am Thorac Soc. 2017 Jul; 14(7):1086-1093.
Score: 0.686
-
COVID-19 Lung Injury and High-Altitude Pulmonary Edema. A False Equation with Dangerous Implications. Ann Am Thorac Soc. 2020 08; 17(8):918-921.
Score: 0.212
-
Cardioprotection of benzolamide in a regional ischemia model: Role of eNOS/NO. Exp Mol Pathol. 2018 12; 105(3):345-351.
Score: 0.187
-
Effect of acetazolamide and methazolamide on diaphragm and dorsiflexor fatigue: a randomized controlled trial. J Appl Physiol (1985). 2018 09 01; 125(3):770-779.
Score: 0.182
-
Acetazolamide and N-acetylcysteine in the treatment of chronic mountain sickness (Monge's disease). Respir Physiol Neurobiol. 2017 12; 246:1-8.
Score: 0.172
-
Findings of Cognitive Impairment at High Altitude: Relationships to Acetazolamide Use and Acute Mountain Sickness. High Alt Med Biol. 2017 Jun; 18(2):121-127.
Score: 0.170
-
Inhibition of carbonic anhydrase prevents the Na(+)/H(+) exchanger 1-dependent slow force response to rat myocardial stretch. Am J Physiol Heart Circ Physiol. 2013 Jul 15; 305(2):H228-37.
Score: 0.129
-
Benzolamide perpetuates acidic conditions during reperfusion and reduces myocardial ischemia-reperfusion injury. J Appl Physiol (1985). 2018 08 01; 125(2):340-352.
Score: 0.044